Chronic Kidney Disease Trial, Recruiting NCT05117450 Sponsor: CHU de Reims Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT05117450
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults older than 18 years of age
  • People who have been receiving hemodialysis (a type of kidney treatment that filters the blood) for at least 3 months
  • People who receive hemodialysis three times per week
  • People who receive a blood-thinning medication called heparin during their dialysis sessions
  • People who are covered by French Social Security
  • People who have given their consent to take part in the study

Who may not be able to join:

  • People receiving a type of dialysis called hemodiafiltration (HDF)
  • People who are pregnant or breastfeeding
  • People already taking part in another interventional research study
  • People who are currently deprived of their liberty by a court or government decision
  • Adults who are under legal protection, such as guardianship or curatorship
  • People who have previously had a serious reaction to heparin called HIT (heparin-induced thrombocytopenia)
  • People with bleeding or clotting disorders, whether inherited or developed over time
  • People with certain active diseases affecting blood or other organs, including myeloma, Waldenström disease, or active solid cancers
  • People taking a type of blood pressure medication called ACE inhibitors
  • People who may need a blood transfusion during the study period
  • People whose hemoglobin (a measure of red blood cells) has not been stable — specifically, where the average level in the previous month was below 10 g/dL or above 12 g/dL
  • People who have an active infection or significant inflammation at the time of joining (measured by a blood marker called C-reactive protein being above 25 mg/L)
  • People who need nutrition given directly into the bloodstream during dialysis sessions
  • People who are expected to be hospitalised or have surgery during the study period
  • People whose vascular access (the point where blood is taken in and out during dialysis, such as an arteriovenous fistula or graft) does not allow sufficient blood flow during treatment (confirm with trial site)
  • People using a catheter for dialysis, or a single-needle method on an arteriovenous fistula, on the day of their screening session
  • People for whom more than 4,000 mL of fluid is planned to be removed during the dialysis session on the day of screening

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 03 26 78 41 40

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
CHU de Reims
Registry
ClinicalTrials.gov
Start date
17 November 2021
Est. completion
17 November 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

number of hemodialysis session success without heparin

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov